Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| peripheral blood | 20 studies | 45% ± 12% | |
| lung | 14 studies | 38% ± 14% | |
| intestine | 6 studies | 27% ± 6% | |
| brain | 5 studies | 42% ± 27% | |
| kidney | 5 studies | 43% ± 21% | |
| lymph node | 5 studies | 48% ± 19% | |
| liver | 4 studies | 32% ± 13% | |
| uterus | 4 studies | 26% ± 5% | |
| bone marrow | 3 studies | 48% ± 23% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 10319.70 | 459 / 459 | 91% | 182.12 | 1012 / 1118 |
| kidney | 99% | 6661.85 | 88 / 89 | 90% | 282.99 | 811 / 901 |
| lung | 100% | 24342.94 | 578 / 578 | 87% | 220.46 | 1004 / 1155 |
| thymus | 97% | 6114.90 | 632 / 653 | 84% | 183.03 | 508 / 605 |
| prostate | 98% | 5150.06 | 239 / 245 | 76% | 72.21 | 384 / 502 |
| uterus | 95% | 4944.76 | 161 / 170 | 70% | 127.45 | 320 / 459 |
| adrenal gland | 95% | 7759.81 | 246 / 258 | 64% | 69.20 | 148 / 230 |
| intestine | 92% | 6318.29 | 885 / 966 | 65% | 101.81 | 345 / 527 |
| skin | 69% | 3312.42 | 1253 / 1809 | 79% | 236.64 | 374 / 472 |
| esophagus | 86% | 3242.40 | 1242 / 1445 | 61% | 73.87 | 111 / 183 |
| bladder | 81% | 4147.67 | 17 / 21 | 62% | 108.42 | 312 / 504 |
| stomach | 65% | 2690.51 | 232 / 359 | 74% | 134.92 | 212 / 286 |
| ovary | 41% | 1275.06 | 73 / 180 | 81% | 175.40 | 350 / 430 |
| pancreas | 22% | 692.87 | 72 / 328 | 87% | 155.61 | 155 / 178 |
| brain | 39% | 1873.32 | 1031 / 2642 | 62% | 116.65 | 439 / 705 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 680.87 | 29 / 29 |
| spleen | 100% | 27050.33 | 241 / 241 | 0% | 0 | 0 / 0 |
| adipose | 100% | 11334.45 | 1199 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 95% | 22494.15 | 883 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 93% | 7377.83 | 1247 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 89% | 180.36 | 40 / 45 |
| liver | 35% | 980.10 | 79 / 226 | 48% | 54.02 | 193 / 406 |
| heart | 78% | 2570.67 | 671 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 39% | 55.53 | 31 / 80 |
| muscle | 26% | 644.17 | 210 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0050870 | Biological process | positive regulation of T cell activation |
| GO_0042102 | Biological process | positive regulation of T cell proliferation |
| GO_0002503 | Biological process | peptide antigen assembly with MHC class II protein complex |
| GO_0006955 | Biological process | immune response |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
| GO_0032729 | Biological process | positive regulation of type II interferon production |
| GO_0050778 | Biological process | positive regulation of immune response |
| GO_0071346 | Biological process | cellular response to type II interferon |
| GO_0031902 | Cellular component | late endosome membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0030666 | Cellular component | endocytic vesicle membrane |
| GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
| GO_0032588 | Cellular component | trans-Golgi network membrane |
| GO_0009986 | Cellular component | cell surface |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0098553 | Cellular component | lumenal side of endoplasmic reticulum membrane |
| GO_0042613 | Cellular component | MHC class II protein complex |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0012507 | Cellular component | ER to Golgi transport vesicle membrane |
| GO_0030658 | Cellular component | transport vesicle membrane |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0023026 | Molecular function | MHC class II protein complex binding |
| GO_0032395 | Molecular function | MHC class II receptor activity |
| GO_0042605 | Molecular function | peptide antigen binding |
| Gene name | HLA-DPA1 |
| Protein name | HLA class II histocompatibility antigen DP alpha chain (HLA-DPA1 protein) (HLA-DPA1*02:01:01:NEW) (MHC class II antigen) MHC class II antigen MHC class II DP alpha chain HLA class II histocompatibility antigen DP alpha chain (MHC class II DP alpha chain) (MHC class II antigen) HLA class II histocompatibility antigen, DP alpha 1 chain HLA class II histocompatibility antigen DP alpha chain (HLA-DPA1*01:03:01:New) (MHC class II antigen) HLA class II histocompatibility antigen, DP alpha 1 chain (DP(W3)) (DP(W4)) (HLA-SB alpha chain) (MHC class II DP3-alpha) (MHC class II DPA1) MHC class II protein HLA class II histocompatibility antigen DP alpha chain Major histocompatibility complex, class II, DP alpha 1 HLA class II histocompatibility antigen DP alpha chain (MHC class II antigen) HLA-DPA1 protein |
| Synonyms | HLASB HLA-DPA HLA DPA1 HLA-DP1A |
| Description | FUNCTION: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. |
| Accessions | Q49U65 Q49U45 A0A140T9M9 Q67AS8 A0A2K9UYS3 A0A895HRT0 A0A7T8GEJ4 A0A6B7IDL4 A0A2U7NN82 A0A7T8JPT0 Q67AU5 A0A678ZVI0 Q67AU3 A0A346MPT8 A0A140T961 A0A678ZWH5 G3GJV6 A0A140T8Z9 A0A5H2UHZ4 A0A2U7NEH8 A0A2K9UYS2 Q67AU8 A0A455JWJ2 ENST00000417724.1 Q9TQA9 A0A140T909 A0A8E4J7S9 A0A2U7MWR8 Q67AM0 A0A678ZGL1 Q29ZN3 ENST00000415247.6 A0A516UVP7 A0A3S6RHQ8 A0A140T992 A0A6B7ICQ7 A0A2U7N9X4 A0A493QPE4 A0A8E4J6Q0 D9YLZ6 A0A6B7HHJ1 A0A5A4LUX5 A0A7T8GEA3 A0A2K9UYS7 A0A8F4JCE7 ENST00000425105.5 A0A6B7HG59 A0A6B7G179 A0A286MCJ2 Q67AM5 Q67AT4 A0A5H2UED3 ENST00000429960.1 A0A4P8JBL0 ENST00000515317.5 A0A2K9UYS6 A0A4P2SSF2 A0A6G8IRB1 A0A8F5FTR8 A0A5P8TXN6 A0A455JWM4 A0A3S6RJR0 A0A140T9W9 A0A140T9G9 ENST00000437676.1 A0A6G8IQS1 A0A2U7MZV6 A0A6B7HGD0 A0A5A4LI15 A0A8E6Z9V6 A0A4P2SSF4 A0A5J6V0Z8 A0A678ZGF0 A0A7L7TNE1 Q95HB9 Q29ZN1 ENST00000441306.1 A0A140T977 A0A5H2UYC3 ENST00000456525.1 A0A7L4X722 Q9XS09 A0A482N7Y0 Q67AR8 Q67AN0 ENST00000441483.1 A0A6B7IBD8 A0A493QPE5 A0A2U7N6Y4 A0A2U7MWS2 A0A6B7HG51 A0A5P8TXJ6 Q29ZN0 A0A140T900 Q67AU4 A0A6B7IDJ6 A0A6B7HFR6 A0A8E4J4F3 ENST00000428180.1 Q49U69 A0A140C6V4 Q49U49 A0A7L7TUJ7 ENST00000437811.1 A0A6B7HHL0 A0A678ZLR6 ENST00000439393.1 A0A5H2UI04 A0A8F5FVW2 A0A7T8GEA5 A0A2U7MZW9 Q49U67 A0A678ZGE3 A0A4Y5R8K1 J9UEA6 A0A7L7TM95 Q67AM7 A0A8E4NGP8 A0A5J6V154 A0A5A4LL11 ENST00000452619.1 A0A6B7IBD4 A0A649ZUX1 A0A5P8TXE8 A0A5J6V209 Q67AU0 A0A6B7IDQ7 A0A678ZHZ5 A0A7T8GE61 A0A4Y5RXA2 ENST00000447657.1 A0A6B7IAL9 A0A3S6RHQ4 Q49U63 A0A5H2UHE7 A0A172WC72 A0A6B7G282 A0A2U7NH39 A0A7U3TZB1 A0A4P8DKR4 A0A6G8IQR3 A0A3S6RJR1 A0A8F5ISY2 A0A7T8JPL9 A0A140T9M7 Q49U57 A0A6B7G308 A0A7T8JQ81 A0A5H2UF15 ENST00000437123.1 A0A4P8DL26 Q49U61 A0A5H2UEC6 A0A8E4NFD7 Q67AM3 A0A2U7NN75 A0A2U7N3L4 A0A455JWR1 A0A5J6V1V8 A0A7T8GDW8 A0A172WC80 F6V115 Q67AS2 A0A172WC76 A0A2U7N9W8 A0A455JWQ7 X5CMJ1 A0A5A4LIZ2 A0A5H2UHF9 A0A6B7G4V6 A0A8E4J4D7 Q67AS9 Q67AL9 A0A5H2UUP6 A0A7T8GED1 A0A6B7ICS0 H0Y6F8 A0A6B7HGC0 Q29ZM9 A0A4Y6GS51 K4PDP4 A0A7T8JP82 I2G9G1 A0A5H2UYQ0 A0A7D5G264 Q67AM9 A0A140T9U1 A0A6C0VBK0 ENST00000436183.1 O78000 A0A5H2V0V4 Q9TPP2 A0A7T5V8X6 ENST00000448742.1 A0A172WC90 A0A2U7MWS4 Q67AU1 A0A140T980 A0A6B7KVI2 ENST00000374808.6 A0A2U7NEI5 A0A172WC77 Q67AU7 A0A3S6RHS4 A0A2U7NEG9 A0A8E4NFZ0 A0A6B7IAL5 A0A6M6CDL2 Q67AM8 A0A2U7NH33 A0A6B7IC79 A0A7T8GE44 A0A140T9G7 A0A140T9G4 A0A5H2UUQ5 Q67AU2 A0A140T9J4 ENST00000414177.1 Q67AT9 A0A4P2STU2 A0A7S6TDL2 A0A1L5LC20 A0A5H2UYD1 A0A140T9Y9 A0A6B9RYR6 A0A8F2TDF0 A0A6B7G1R0 A0A455JWE4 Q49U71 A0A2U7MWQ8 A0A6C0X4T0 A0A6B7G4B4 A0A140T9Y8 A0A8E4NFZ6 A0A5A4LJY2 Q49U35 A0A4P8DLC9 ENST00000422504.5 Q49U51 A0A286MCJ1 A0A140T9R4 A0A141R7F7 A0A7T8GED4 A0A6H1PR27 Q49U47 Q29ZN4 A0A858B6K6 ENST00000443117.5 A0A6B7KXP6 A0A455JT65 A0A172WCC2 A0A5P8I422 A0A8F7CGI1 Q49U39 A0A140T9U4 Q49U59 A0A3S6RHQ7 A0A5B9R3V4 A0A140T9H1 A0A5H2UU41 A0A678ZW68 A0A6B7KVE4 Q67AN1 A0A7S9YVJ3 A0A6B7HG96 ENST00000419452.1 A0A2U7N6Y1 Q67AU9 A0A6G8IQI7 A0A455JV10 H9BIJ2 A0A0C7DV97 A0A140T9A6 A0A6B7HG47 A0A8F7CI98 A0A5P8TY43 A0A2U7MWR7 O98050 Q67AM1 Q67AT8 A0A2U7NIE8 A0A140T944 ENST00000432811.1 A0A6B7HGB5 ENST00000515346.1 N0A0E5 Q49U41 A0A8F5IUS6 A0A678ZWG8 A0A140EDI1 A0A455JXG4 A0A7T8GDD9 A0A6B7G1D9 A0A140T989 A0A7T7GVM5 A0A8E4J5N4 A0A6B9RYU0 ENST00000439867.1 ENST00000442259.1 A0A2K9UYU3 P20036 Q49U43 A0A4P2STD9 A0A6G8IQR5 A0A140T9W1 Q49U53 J3KQ99 A0A5H2UU33 Q67AM4 ENST00000692443.1 A0A140T9F8 A0A678ZZ32 A0A140T9D6 A0A140EDI6 Q5EY04 A0A482CVI8 Q49U33 A0A6M8DJH8 A0A5H2USY3 Q67AN2 A0A7L7TMD7 A0A172WC74 A0A8F7CGH5 A0A4P2ST17 ENST00000439571.1 Q49U29 A0A8E4J4D2 A0A140T968 A0A4P2SV01 A0A5H2UYP4 A0A7L4X6P9 A0A6M6CE24 A0A5A4LHS6 Q9TQB0 V5N4B3 A0A140T914 X5CKE2 Q67AM2 A0A2U7N3L8 A0A2U7NIE6 A0A455JUM6 A0A6M6CG77 A0A5B9R1K9 Q49U55 ENST00000453337.1 ENST00000512750.1 Q67AU6 A0A7L7TQK4 A0A6B9XJ98 A0A6B7HFH3 ENST00000454805.5 A0A2U7N3L1 A0A678ZKG5 Q49U37 Q67AM6 A0A678ZI04 A0A4P8JBH1 A0A2U9K708 A0A172WC73 A0A6B7HG46 A0A7T8JP05 A0A172WCA5 A0A858LJD1 A0A455R0B2 A0A455JT72 A0A4V0NPC5 ENST00000427518.1 ENST00000453314.1 Q49U31 A0A2U9K719 A0A6M6CDS5 ENST00000419277.5 ENST00000414003.1 A0A6B7G262 A0A678ZGB1 A0A5H2UF05 ENST00000413109.1 A0A172WC68 Q29ZN2 A0A172WC71 ENST00000423630.1 Q49U27 A0A6M6CE93 ENST00000455869.1 A0A8F7CGG0 ENST00000383224.6 ENST00000448154.1 A0A5H2USX7 A0A5H2V0V0 |
